Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icalcaprant PK in Healthy Japanese and Han Chinese Adults
NCT06722417Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of icalcaprant in bipolar disorder (BD) and major depressive disorder (MDD) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Observed Plasma Concentration up to 6 days, Time to Cmax up to 6 days and 5 more. Started Nov 2024; status: completed.
02
Drugs
icalcaprant
03
Conditions
bipolar disorder (BD)major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06722417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06722417.